# A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson's Disease

> **NIH NIH U01** · MASSACHUSETTS GENERAL HOSPITAL · 2020 · $2,156,445

## Abstract

Non-motor symptoms (NMS) are some of the most disabling manifestations of Parkinson’s disease (PD).
Disrupted sleep and alertness are among the most common NMS. These aspects of PD affect as many as 90%
of patients; contribute to poor quality of life, impaired mood and cognition, and increased risk for accidents; and
lead to increased morbidity and mortality. Mechanisms leading to NMS are not well understood and treatment
options remain limited. The endogenous human circadian system has a critical role in the regulation of sleep and
alertness and is most effectively synchronized by environmental light stimuli. Our pilot clinical trial suggested
beneficial effects of twice-daily bright light therapy (LT) on sleep and alertness in PD. Several other recent studies
have revealed similar beneficial effects of LT in PD. While these outcomes of LT are encouraging, dosing aspects
of LT require further study before translation to clinical practice.
This project aims to investigate one central aspect of dosing of LT: the frequency of LT. Dose frequency will
influence adherence and tolerability as well as the clinical effect of LT. In our proposed work, 144 PD patients
with impaired sleep by self-report will be randomized to receive (i) bright-white LT (BWLT) twice daily (morning
and evening), (ii) BWLT once daily (evening only), (iii) BWLT once weekly (evening only), and (iv) dim-red LT
(DRLT) twice daily (morning and evening) in one-hour blocks for eight weeks using a commercially available
lightbox. Outcomes will include safety, and measures of sleep, alertness, fatigue, motor and non-motor
symptoms, and quality of life. Throughout the study, participants will wear a wrist actigraph for continuous
monitoring of sleep-wake patterns, and keep daily sleep diaries and records of their LT exposure. Aim 1 will
utilize a comparative selection design to determine whether either daily dose of BWLT improves sleep in PD
sufficiently to carry forward into a phase III efficacy trial and, if so, which dose frequency to carry forward. Aim 2
will (i) assess whether once-weekly BWLT is an appropriate but lower burden control condition relative to twice-
daily DRLT; (ii) estimate the effect of daily BWLT on fatigue in PD; and (iii) determine whether patients adhere
to LT. Exploratory analyses will estimate the effect of daily BWLT on overall PD symptom severity, motor and
non-motor symptoms, objective measures of sleep, quality of life, mood, and cognition.
Long-term, this project addresses the need to develop novel treatments for impaired sleep and other NMS
associated with PD. Short-term, the project will provide a foundation for a future phase III clinical trial of LT by
determining the optimal frequency of BWLT and the appropriate control condition. This project is responsive to
several highest priority areas for clinical research outlined in the most recent (2014) NINDS PD Research
Consensus Meeting and in the 2011 NIH Sleep Disorders Research Plan: (i) to develop ef...

## Key facts

- **NIH application ID:** 10012951
- **Project number:** 5U01NS114001-02
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Aleksandar Videnovic
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $2,156,445
- **Award type:** 5
- **Project period:** 2019-09-15 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10012951

## Citation

> US National Institutes of Health, RePORTER application 10012951, A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson's Disease (5U01NS114001-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10012951. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*